Table 6.
ARFL and PSMA conversion at PD. Percentages refer to the fraction of patients within groups who at baseline shared biomarker constellation (first column). Numbers in brackets refer to the number of patients with specific PSMA/ARFL profile/total number of patients analyzed at PD.
| Progressive Disease (PD) | |||||
|---|---|---|---|---|---|
| Baseline | PSMA+ ARFL+ |
PSMA+ ARFL− |
PSMA− ARFL+ |
PSMA− ARFL− |
no CTCs |
| PSMA+, ARFL+ (14) | 71.4% (10) | 0 | 7.1% (1) | 0 | 21.4% (3) |
| PSMA+, ARFL− (3) | 33.3% (1) | 66.7% (2) | 0 | 0 | 0 |
| PSMA−, ARFL+ (3) | 66.7% (2) | 0 | 0 | 0 | 33.3% (1) |
| PSMA−, ARFL− (2) | 50% (1) | 0 | 0 | 0 | 50% (1) |
| no CTCs (3) | 33.3% (1) | 0 | 0 | 0 | 66.7% (2) |
| Total (25) | 15 | 2 | 1 | 0 | 7 |